Musculoskeletal tissue degeneration is generally thought to be an age-related process that may be aggravated or accelerated by injury or disease ([@CIT0047]). It has been well established that the cellular and molecular processes during degeneration can be directly associated with those happening during aging. During the last 3 decades, research has shown that apart from the many environmental stimuli, genetic factors play an important role in the regulation of aging ([@CIT0063]). More recently, the role of micro RNAs (miRNAs) as regulators of aging of cells and organisms has been increasingly studied ([@CIT0028], [@CIT0074], [@CIT0087]). These short and non-coding RNAs regulate the translation of mRNAs at the posttranscriptional level, and therefore widely influence the biological function of cells. Currently, around 1,400 different human miRNAs have been identified and reported in miRBase (<http://www.mirbase.org>). In terms of aging, a number of miRNAs have been shown to be up- or downregulated; thus, they are believed to play a key role in regulation of aging processes ([@CIT0020], Weilner et al. 2012).

In this review article, we first describe the present state of research on miRNAs regarding their function in the aging and tissue degeneration processes. We then consider studies that have focused on specific miRNAs that influence aging of cells and organisms. Then we discuss age-related diseases in cartilage and bone that are already being associated with miRNAs. We end by exploring the future role of miRNAs in the field of orthopedic research.

MiRNAs and cellular aging {#ss1}
=========================

The phenomenon of irreversible cellular growth arrest of normal human cells after serial passage in vitro is called cellular senescence, and was first described by [@CIT0022]. This cell cycle block can be caused by critically short telomeres, DNA damage, oncogenic signaling, or cellular stress. Senescent cells are not only characterized by a changed morphology and function but also by altered intracellular protein expression and an altered secretion profile compared to early-passage cells ([@CIT0009]). It was long believed that cellular senescence is just an in vitro phenomenon, but in recent years an increasing number of papers have been published showing not only that senescent cells accumulate with age in vivo---for instance, in the skin ([@CIT0024], [@CIT0027]), at sites of arteriosclerosis ([@CIT0014]), or in the kidney ([@CIT0052], [@CIT0034])---but that they also contribute to overall aging and age-related diseases in an organism. For example, [@CIT0003] demonstrated that the onset of age-related diseases could be delayed by removing p16Ink4a-positive cells, a typical marker for cellular senescence, in mice. Furthermore, the influence of senescent cells in aging of an organism was also shown by reactivating telomerase in mouse tissues, which subsequently "became rejuvenated" ([@CIT0026], Bernardes de [@CIT0006]). Today, 2 pathways are known whose activation can lead to cellular senescence. Firstly, replicative senescence is triggered by exhausted replicative potential caused by critically short telomeres ([@CIT0009]). Secondly, stress can induce premature senescence, triggered by cellular stressors such as DNA damage or oncogenic signaling ([@CIT0010]). Whatever the trigger for cellular senescence, so far the 2 executors of irreversible cell cycle arrest appear to be the p21- and the p16-dependent pathways. Both pathways result in activation of the retinoblastoma cell cycle inhibitory pathways, leading to cell cycle arrest, possibly followed by permanent growth arrest and cellular senescence ([@CIT0009]).

Interestingly, even in musculoskeletal tissue such as bone and cartilage, accumulation of senescent cells with age has been observed. Mesenchymal stem cells (MSCs) are the source of bone matrix-forming osteoblasts and of cartilage matrix-forming chondroblasts. Since bone is continuously remodeled, a functionally adequate number of proliferating and differentiating stem cells for tissue regeneration is required. A number of studies (reviewed by [@CIT0030]) examining differences in the number of colonies formed by MSCs isolated from young and aged donors, led to rather contradictory results. In summary, a strong decline in the number of MSCs can be observed in early adulthood as soon as skeletal growth is completed, but this reduction does not contribute to the frequently observed reduction in bone matrix density in old age ([@CIT0030]). Although no conclusive reduction in the number of MSCs after the completion of skeletal growth has been found so far, a higher percentage of MSCs, exhibiting typical markers of senescence---such as β-galactosidase---was observed in cultures established from elderly donors, indicating that senescent MSCs accumulate in vivo with age, and that they may thereby contribute to age-related bone loss ([@CIT0067], [@CIT0091]). In support of this, a reduced replicative potential of human MSCs ([@CIT0068], [@CIT0037]) and osteoblasts ([@CIT0031]) isolated from elderly donors compared to young individuals has been reported.

Furthermore, increased levels of the senescence-inducing proteins p53 and p21 have been observed in aged MSCs ([@CIT0091]). Interestingly, p53 has been shown to have an impact on osteogenesis of MSCs, since p53 knock-down resulted in the initiation of osteogenic differentiation ([@CIT0033]. Taken together, these studies show that the proportion of senescent MSCs increases with population doubling in vitro as well as with donor age, and these observations are associated with reduced differentiation capacity.

It is not only MSCs and osteoblasts that have been shown to enter cellular senescence. Chondrocytes of aged donors have been found to show typical markers of senescence, such as reduced telomere length and enhanced β-galactosidase expression compared to young donors ([@CIT0051]). In addition, transfection of chondrocytes isolated from an elderly donor with the gene for telomerase reverse transcriptase hTERT not only resulted in elongated telomeres, but also enabled the transduced cells to undergo 275 more population doublings compared to normal cells, indicating that chondrocytes also are affected by replicative senescence ([@CIT0051]).

Another example of senescent cells and their contribution to the age-associated degeneration of cartilage was provided by Hoyland's group. They hypothesized that the reason for degenerated intervertebral discs may be senescent cells. Comparing cells isolated from non-degenerated and degenerated human tissue, reduced telomere length, reduced replicative potential, increased p16INK4A levels, and a higher proportion of senescence-associated β-galactosidase-positive cells were detected in cell cultures isolated from degraded tissues. Even when cells isolated from 2 discs of the same individual were compared, differences in their mean telomere length could be observed, depending on the grade of tissue degradation ([@CIT0038]). Summarizing the data, it is clear that cells known to be relevant to musculoskeletal tissue are also affected by cellular senescence, and that they accumulate with age or when there is musculoskeletal disease.

MiRNAs are single-stranded 22- to 24-nucleotide non-protein coding RNAs that have the ability to inhibit protein translation by recognizing and binding to the 3´-untranslated region of specific target mRNAs ([Figure](#F1){ref-type="fig"}). In 1993, the first miRNA, lin-4, was discovered in Caenorhabditis elegans (C. elegans) ([@CIT0039]), and more than 10 years later, elevated levels of lin-4 were found to have a positive effect on the lifespan of the nematode ([@CIT0007]). MiRNAs not only target 1 but up to several hundred mRNAs, resulting in the capability to repress the expression of components within one pathway, and even in related pathways. Thus, they can rapidly control cellular processes such as differentiation, proliferation, migration, autophagy, apoptosis, and senescence ([@CIT0004], [@CIT0090], [@CIT0073]), but they also affect processes of the entire organism---such as aging ([@CIT0007]). The importance of miRNAs in bone formation in adult organisms is highlighted by the results of several studies showing that deletion of Dicer, a protein necessary for biogenesis of miRNA in mature osteoblasts and in osteoclasts leads to a high-bone-mass phenotype in mice ([@CIT0069], [@CIT0018], [@CIT0056]).

![MicroRNAs (miRNAs) control the translation of messenger RNA (mRNA) into protein. Binding of miRNA to a target mRNA inhibits protein expression. Inhibitors of miRNA block the function of miRNA and therefore enhance translation.](ORT-86-092-g001){#F1}

How do miRNAs and senescence interact? {#ss2}
--------------------------------------

Originally, different miRNA expression profiles in replicative senescence were shown for various cell types, such as arterial and umbilical vein-derived endothelial cells, replicated CD8(+) T cells, renal proximal tubular epithelial cells, and skin fibroblasts ([@CIT0049], [@CIT0021], [@CIT0060]), indicating that miRNAs might play an important role in orchestrating replicative senescence. Also, in the case of human bone marrow-derived MSCs, an altered miRNA expression profile due to cellular senescence was observed. In particular, upregulation of miR-369-5p, miR-29c, and let-7f was demonstrated in replicative senescence ([@CIT0076]). However, whether the altered miRNA profile is a consequence of senescence or whether the altered miRNA profile triggers replicative senescence is still a matter of debate. Another prominent example of miRNAs being differentially regulated during senescence is miR-34a. This miRNA is highly expressed in senescent fibroblasts ([@CIT0071]), endothelial cells, and in the heart and spleen of aged mice, suggesting a possible role of miR-34 in cardiovascular diseases ([@CIT0025]). MiR-34a is known to target the class-III histone deacetylase silent information regulator 1 (SIRT1) ([@CIT0082]), and expression of miR-34a---which leads to reduced SIRT1 levels---contributes to a positive p53-activating feedback loop leading to increased p21 levels, thereby triggering senescence ([@CIT0083]). Regarding bone formation and tumorigenesis in bone, expression of miR-34a has been found to decrease in osteosarcoma cell lines ([@CIT0084], [@CIT0045]). Furthermore [@CIT0084] demonstrated that overexpression of miR-34a inhibits the tumor growth and metastasis of osteosarcoma. This observation was confirmed by [@CIT0042], who demonstrated that tumor cells overexpressing miR-34a have reduced replicative potential, indicating that this miRNA does indeed have an effect on cell cycle progression. However, whether the observed downregulation of miR-34a in osteosarcoma directly impairs bone formation, or whether the enhanced formation is due to a prevention of senescence, which would otherwise inhibit tumor formation, is not clear ([@CIT0023]).

MiRNAs are not only differentially regulated during replicative senescence, but also in stress-induced premature senescence ([@CIT0040], [@CIT0012], [@CIT0043]). Regarding bone formation, data on miRNA expression profiles during senescence have shown changes in irradiation-induced prematurely senescent osteoblasts compared to early-passage cells ([@CIT0044]). Other studies detected the miR-17-92 cluster, a group of miRNAs that were found to be downregulated in low-level irradiation-induced senescent cells ([@CIT0048], b) but upregulated in osteosarcoma cell lines ([@CIT0005]), indicating that this family of miRNAs might also play a critical role in controlling cell cycle progression during bone formation.

Oxidative stress has been shown to induce premature cellular senescence in various cell types ([@CIT0064], [@CIT0017], [@CIT0088], [@CIT0008], [@CIT0016]). Several studies have demonstrated that miRNAs play an important role in reactive oxygen species-induced senescence ([@CIT0053], [@CIT0025], [@CIT0002], [@CIT0050], [@CIT0012]). [@CIT0050] reported that miR-200c is upregulated upon H2O2 treatment of human endothelial cells, and that overexpression of miR-200c alone causes growth arrest, apoptosis, and cellular senescence. Interestingly, [@CIT0045] reported that miR-200b and miR-200c are usually downregulated in osteosarcomas and that overexpression of those 2 miRNAs leads to a reduced proliferation potential, indicating that these miRNAs do indeed affect cell cycle progression in bone-relevant cells ([@CIT0045]). However, whether the altered miRNA profile is a consequence of stress-induced senescence or of the DNA damage afflicted remains unclear.

What is the functional consequence of miRNAs in senescence? {#ss3}
-----------------------------------------------------------

Differential miRNA expression of various cellular senescenct cell types strongly suggests functional consequences of the differentially expressed miRNAs in the context of cellular aging, for which we present only some examples, predominantly of studies of bone-derived tumor cells.

It has been shown that miR-21 levels are upregulated in osteosarcoma cell lines, and that its overexpression correlates with enhanced cell invasion and migration of tumor cells by targeting and inhibiting the expression of reversion-inducing cysteine-rich protein with kazal motifs (RECK), a protein that negatively regulates matrix metalloproteinase-9 (MMP-9) ([@CIT0092]). It has also been shown that miR-21 expression is downregulated in bone marrow-derived MSCs of postmenopausal patients suffering from osteoporosis, as well as in ovariectomized mice ([@CIT0085]). Recombinant expression of miR-21 in murine MSCs resulted not only in enhanced osteoblastogenesis in vitro, but also in increased bone formation in vivo ([@CIT0085]).

Another prominent example of miRNAs playing an important role in the process of cellular senescence is miR-24. MiR-24 targets p16 mRNA and is downregulated in replicative senescent diploid fibroblasts ([@CIT0036]), thereby promoting the p16-dependent senescence pathway. Interestingly, miR-24 has also been shown to have a key role in facilitating osteogenesis of MSCs ([@CIT0019]). It is therefore tempting to speculate that reduced miR-24 levels contribute to the phenomenon of reduced proliferation potential, by facilitating p16-mediated senescence, as well as to decreased osteogenic differentiation potential of MSCs with age.

Not only p16, but also p21---as an ultimate effector of senescence---has been shown to be regulated by miRNAs. Apart from miRNAs such as miR-663, the miR-17-92 cluster is a prominent example of the posttranscriptional repression of p21 through miRNAs ([@CIT0086]). This cluster has not only been reported in the context of cell cycle regulation, but also to be differentially expressed in various cancer cell lines including osteosarcomas ([@CIT0072]).

MiRNAs and age-related diseases in cartilage and bone ([Table](#T1){ref-type="table"}) {#ss4}
======================================================================================

Several studies have revealed that miRNAs play a central role in age-related diseases such as cardiovascular diseases, Alzheimer's disease (AD), arthritis, dementia, cataract, osteoporosis, diabetes, and cancer (as reviewed by [@CIT0061]). Here are a few examples of deregulated miRNAs in patients suffering from age-related diseases (involving bone or cartilage).

###### 

Some miRNAs of importance for bone and joint

  --------------- ---------------------------------------------- ------------------------
  miRNA 34a       decreased bone formation                       [@CIT0084], [@CIT0045]
  miRNAs 200b/c   decreased bone formation                       [@CIT0045]
  miRNA 21        osteoporotic patients, ovx rats                [@CIT0085]
  miRNA 21        increased bone formation                       [@CIT0085]
  miRNA 24        decreased osteogenic differentiation of MSCs   [@CIT0019]
  miRNA 34a       osteoarthritis                                 Abouheifet et al. 2010
  miRNA 146a      cartilage preservation                         [@CIT0042]
  miRNA 133a      osteoporotic patients                          [@CIT0046], [@CIT0078]
  miRNA 138       osteoporotic mice                              [@CIT0015]
  miRNA 148a      increased bone mass                            [@CIT0011]
  miRNA 2861      reduced osteogenesis                           [@CIT0040]
  --------------- ---------------------------------------------- ------------------------

Several studies have demonstrated the importance of miRNAs in cartilage development, maintenance, and destruction ([@CIT0070], [@CIT0074], [@CIT0065], [@CIT0066], [@CIT0029], [@CIT0075]). miRNA expression profiles were established using chondrocytes isolated from patients with osteoarthritis and compared to those from healthy age matched controls. 7 differentially regulated miRNAs were found, among them hsa-miR-483-5p, which was more highly expressed in cells of osteoarthritic donors ([@CIT0013]). In contrast, hsa-miR-149\*, hsa-miR-582-3p, hsa-miR-1227, hsa-miR-634, hsa-miR-576-5p, and hsa-miR-641 were downregulated in osteoarthritis. Interestingly, these miRNAs have been shown to influence pathways associated with cartilage function ([@CIT0013]). In this regard, it was also shown that SIRT1 levels are deregulated in osteoarthritis chondrocytes. It is known that SIRT1 expression levels are tightly regulated by miRNAs, and it has already been shown that SIRT1 levels change during the development of osteoarthritis ([@CIT0013]). One example of miRNA that has an influence on SIRT1 expression levels is miR-34a. It has been shown that miR-34a levels are upregulated in response to activated p53, and in turn inhibit the expression of SIRT1 ([@CIT0089]). Interestingly, elevated levels of miR-34a contribute to osteoarthritis, since silencing of miR-34a in an osteoarthritis rat model resulted in reduced cartilage destruction ([@CIT0001]). A positive effect on the preservation of cartilage in an osteoarthritis mouse model was observed on overexpression of miR-146a ([@CIT0042]). miRNAs have also been shown to have a high impact in other age-related diseases such as osteoporosis or osteopenia. Several miRNAs are known to influence the function of bone-forming osteoblasts. For example, miR-133a was not only shown to inhibit osteoblastogenesis by targeting Runx-2 but it also turned out to be a potential biomarker, since miR-133a levels are higher in patients suffering from osteoporosis than in healthy postmenopausal women ([@CIT0046], [@CIT0078]).

Another promising candidate for a marker of osteoporosis is miR-214, the expression of which negatively correlates with alkaline phosphatase and osteocalcin levels---2 established markers of bone formation ([@CIT0077]). Furthermore, overexpression of miR-138, which has been shown to inhibit osteogenic differentiation of MSCs in vitro, was also found to cause an osteoporotic phenotype in mice ([@CIT0015]). MiR-182 suppresses osteogenesis of bone-forming osteoblasts by knocking down its target, Forkhead box O1 (FOXO1) ([@CIT0032]). On the other hand, some miRNAs are known to enhance the activity of bone-resorbing osteoclasts. MiR-148a was recently shown to increase osteoclastogenesis in vitro by knocking down the expression of V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) ([@CIT0011]). In support of this, the group of Luo could demonstrate that inhibiting miR-148a expression in vivo led to impaired osteoclast development and increased bone mass in ovariectomized (OVX) and sham-operated control mice ([@CIT0011]).

The influence of miRNAs on the development of osteoporosis was demonstrated by a study by [@CIT0040]. MiR-2861 was shown to target histone deacetylase 5 (HDAC5), a protein facilitating Runx2 degradation ([@CIT0041]). Silencing of miR-2861 resulted in reduced osteogenesis in mice ([@CIT0041]). Furthermore, these authors also reported on 2 young, related individuals who were suffering from primary osteoporosis due to mutations in miR-2861.

The future role of miRNAs in musculoskeletal research {#ss5}
=====================================================

The high potential of miRNAs as diagnostic markers or biomarkers has been mentioned on several occasions ([@CIT0054], [@CIT0035], [@CIT0080], [@CIT0059], [@CIT0055]). As the majority of studies have focused on the intracellular role of miRNAs, it was only recently that they were also detected in blood and other body fluids ([@CIT0055]). [@CIT0054] were the first to describe stable circulating miRNAs in cancer patients, which was subsequently supported by findings in other studies ([@CIT0035], [@CIT0080]). In terms of arthritis, [@CIT0059] showed an increased expression of miR-146a in peripheral blood mononuclear cells from patients with rheumatoid arthritis. [@CIT0057] described miRNAs in the synovial fluid of patients with rheumatoid arthritis and osteoarthritis. MiR-16, miR-146a, miR-155, and miR-223 were all found to be at higher levels in synovial fluid in rheumatoid arthritis than in osteoarthritis. MiRNAs as biomarkers in synovial fluids appear to be a very exciting field for further research; the development of disease-specific profiling using synovial fluid and peripheral blood could be especially promising. Regarding osteoarthritis and posttraumatic arthritis, the role of extracellular miRNAs in signaling that directly activates the arthritic process has been mentioned ([@CIT0081]). We have recently reviewed that extracellular miRNAs are packed in secretory microparticles, such as exosomes, thus being transferable from tissue to tissue ([@CIT0079]). [@CIT0055] mentioned that extracellular miRNAs may play a role similar to cytokines, and could be considered to be paracrine regulatory molecules for cell-to-cell or tissue-to-tissue communication. They also pointed out that the mechanisms involving transport and functions of exosomes are not yet well understood and need to be explored further. This may not only lead to new biomarkers, but may also introduce novel therapeutic targets in osteoarthritis.

[@CIT0078] described miR-133a in human peripheral blood monocytes as a potential biomarker of postmenopausal osteoporosis. MiR-133a was more highly expressed in the low bone mineral density group than in high bone mineral density group ([@CIT0078]). They found 3 potential osteoclast-related target genes---CXC11, CXCR3, and SLC39A1---which are known to play an important role in osteogenesis ([@CIT0078]).

The use of miRNAs as therapeutic agents in joint diseases was demonstrated by [@CIT0058]. They injected double-stranded miR-15a into arthritic joints of mice. It was subsequently found in synovial cells but not in chondrocytes. MiR-15a led to increased cell apoptosis by inhibiting the expression of B-cell CLL/lymphoma 2 (BCL-2), which is known to act as an inhibitor of apoptosis and \[authors. OK?\] is overexpressed in rheumatoid arthritis synovial fibroblasts. Another possible therapeutic target might be miR-210. [@CIT0062] reported on the effect of intraarticular injection of miR-210 on partially transected anterior cruciate ligaments in rats. They observed healing of the ligament following injection of miR-210 through enhancement of angiogenesis by upregulation of VEGF and FGF2 expression.

Conclusion {#ss6}
==========

MiRNAs play an important role in the aging process in general, and in age-related diseases ([@CIT0061]). Due to the complexity of the spectrum of intracellular and extracellular miRNAs, our current understanding in this area is far from complete. However, the number of reports on specific miRNAs and their role in tissue degeneration is constantly increasing. With regard to the age-related diseases of the musculoskeletal system, such as osteoporosis and osteoarthritis, promising studies have been undertaken that will contribute to a better understanding of the underlying mechanisms of these conditions. The role of miRNAs as diagnostic biomarkers---tissue-specific as well as in body fluids---has gained enormous research interest recently. Furthermore, it has been shown that miRNAs, both locally and systemically, may be able to be used as therapeutic agents in future.
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